Metformin boosts survival in men with diabetes, prostate cancer

08/6/2013 | MedPage Today (free registration)

Metformin use was associated with a 24% lower risk of all-cause mortality during the first six months of treatment in men with diabetes and prostate cancer compared with nonusers, a study indicated. Researchers also found that each additional six-month period of metformin treatment was tied to 44% lower odds of prostate cancer-specific mortality and a 20% decreased risk of all-cause mortality. The results appear in the Journal of Clinical Oncology.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY